|
Micro-Cap On Track To Meet $14.8 Million 2010 Revenue Projection
By: AllPennyStocks.com News
December 14, 2009
As the H1N1 flu pandemic occupies more and more of the world’s consciousness as the year comes to an end, more of the spotlight is focused on companies that can reduce the risk of further medical trouble as the result of unsafe needles administering the vaccine against the potentially fatal strain. One such company, headquartered in Charleston, South Carolina, announced in mid-December it’s going ahead full-tilt with taking its flagship product into full mass production mode.
Revolutions Medical Corporation (OTCBB:RMCP) makes the RevVac safety syringe, as well as other products such as the RevColor, RevDisplay and Rev3D MRI Technology, and has ramped up manufacture of the RevVac syringe, which not too long ago got the okay from the U.S. Food and Drug Administration (FDA).
RMCP is committed to developing and distributing consistently new products and tools to the medical industry, whether internally or through acquisitions. Its goals are to make health care safer and less expensive by reducing risks and cutting time and expenses.
For reasons discussed above, the world market for safety-engineered medical devices (SEMDs) is projected to exceed two billion this year and is forecasted to maintain a 20% annual growth rate in the near term. The other tools in RMCP’s holster will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion U.S.
Earlier this month, the company exhibited its MRI software products at this week's Radiology Society of North America (RSNA) annual meeting, coming away with rave reviews. A number of these contacts could play an important role in the Company's ongoing efforts to validate clinically specific applications of its MRI tools prior to the 2010 commercial launch.
Timely hot topics at the show included MRI analysis in breast disease, and brain abnormalities such as the depth of injury in concussion (as reported by the NFL) led to discussions as to how the unique MRI color software would aid in image analysis, thereby enhancing diagnostic confidence in an entirely different way.
By hitting its primary milestone, RevMed satisfies its previously announced commitment to begin production in this year’s last fiscal quarter. The company also stays on pace to meet its second-quarter sales launch goal in fiscal 2010 and $14.8-million revenue projection for the coming year.
The stock was an anomaly in March, sustaining its 52-week peak when pretty much everyone else in the market was floundering. The price hit 71 cents a share on March 30, only a matter of week after plumbing the depths at 14 cents in mid-February. The news that the company was stepping up syringe production sent the stock zigzaging, and at last check was down to $0.37, at a significant discount compared to the positive news announced.
Copyright © 2009 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
AllPennyStocks.com has been compensated twenty two thousand five hundred dollars by the company for its efforts in presenting the RMCP profile on its web site and distributing it to its database of subscribers as well as other services. A full disclaimer on RMCP can be found at: http://www.allpennystocks.com/aps_us/company_spotlights/archives/rmcp.asp.
|
